Free Trial
NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

CASI Pharmaceuticals logo
$1.33 0.00 (-0.02%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

Key Stats

Today's Range
$1.30
$1.39
50-Day Range
$1.18
$2.05
52-Week Range
$1.09
$7.67
Volume
12,340 shs
Average Volume
50,938 shs
Market Capitalization
$16.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

CASI Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

CASI MarketRank™: 

CASI Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 96th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about CASI Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CASI Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CASI Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CASI Pharmaceuticals has a P/B Ratio of 11.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CASI Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.33% of the float of CASI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CASI Pharmaceuticals has recently decreased by 35.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CASI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CASI Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.33% of the float of CASI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CASI Pharmaceuticals has recently decreased by 35.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CASI Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for CASI Pharmaceuticals this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.23% of the stock of CASI Pharmaceuticals is held by institutions.

  • Read more about CASI Pharmaceuticals' insider trading history.
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Stock News Headlines

CASI Pharmaceuticals Inc Valuation - Morningstar
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

CASI Stock Analysis - Frequently Asked Questions

CASI Pharmaceuticals' stock was trading at $2.83 at the beginning of 2025. Since then, CASI shares have decreased by 52.0% and is now trading at $1.3590.
View the best growth stocks for 2025 here
.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) announced its quarterly earnings data on Friday, May, 16th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.08. The biotechnology company earned $6.24 million during the quarter, compared to analyst estimates of $7.39 million. CASI Pharmaceuticals had a negative net margin of 129.05% and a negative trailing twelve-month return on equity of 972.55%.

Shares of CASI Pharmaceuticals reverse split on the morning of Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/16/2025
Today
7/03/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CASI
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+194.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.26 million
Net Margins
-129.05%
Pretax Margin
-125.26%

Debt

Sales & Book Value

Annual Sales
$28.54 million
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
11.33

Miscellaneous

Free Float
9,687,000
Market Cap
$16.72 million
Optionable
Optionable
Beta
0.53

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:CASI) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners